Computational chemistry

Universal Display Corporation and Adesis, Inc. Announce Sponsorship and Participation in MARM 2022

Retrieved on: 
Tuesday, May 31, 2022
Technology, General Health, Professional Services, Science, Other Manufacturing, Health, Semiconductor, Alternative Energy, Energy, Chemicals, Plastics, Research, Other Technology, Nanotechnology, Manufacturing, Hardware, Finance, Consumer Electronics, Linda, Chemistry, The College of New Jersey, Universal Display Corporation, Form, Science, technology, engineering, and mathematics, Company, Catalysis, Chemical revolution, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, OLED, Nasdaq, Board of directors, Lighting, Mission statement, University of Pittsburgh College of Business Administration, Associate, Green, UDC, Research, STEM, Brain, Crystal engineering, Industry, Model, Technology transfer, Organic Syntheses, Century, American Chemical Society, CRO, Student, Industrial, Nanotechnology, Computational chemistry, Adoption, ACS, Growth, Security (finance), Television, Management, Fine chemical, Advanced Battery Technologies, Science, Technology, Organic chemistry, Engineering

Universal Display Corporation and Adesis, Inc. are sponsors of MARM 2022.

Key Points: 
  • Universal Display Corporation and Adesis, Inc. are sponsors of MARM 2022.
  • Participants for MARM 2022 include:
    Dr. George Fitzgerald, Director of Computational Chemistry of UDC, is MARM 2022s Division Chair for Industrial and Engineering Chemistry.
  • Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation.
  • Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Science, Health, Research, Â, Chemistry, Department, Medicinal chemistry, Cysteine, Lysine, Proteome, Trubion, Proteomics, Patient, Biology, Science, Therapy, Gilead Sciences, Computational chemistry, Terremoto, Industry, List of life sciences, Time, UCSF, Biotechnology, Toxicity, Third Rock Ventures, The Sun Sessions, Team America: World Police, Protein, HIV, Drug discovery, Cancer, Hepatitis, CEO, Fine chemical, Pharmaceutical industry, Incyte, Tetris

Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.

Key Points: 
  • Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
  • Terremoto is redefining what was once thought of as scientifically impossible with our well-defined platform approach and unrivaled team.
  • Terremoto leverages its covalent drug discovery and development engine to create highly targeted, small molecule medicines for a broad spectrum of severe diseases, including cancer.
  • Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy.

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022

Retrieved on: 
Thursday, May 19, 2022
Company, IVA, Pharmacology, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, NASH, ISIN, Exercise, Degenerative disease, Patient, AbbVie, Biology, AMF, California Labor Code, Review, Pharmacokinetics, Clinical trial, Nasdaq, Computational chemistry, COVID-19, Disulfiram-like drug, Adult, Mucopolysaccharidosis, Research, MPS, Intention, Program, Chronic liver disease, Safety, Sale, Treasury, Security (finance), Growth, Factor X, VI, Annual report, Share repurchase, Medical device, Reinsurance, Pharmaceutical industry, Euronext Paris

Pursuant to Article 241-2 of the AMF General Regulations (Rglement Gnral de lAutorit des marchs financiers), the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the Company) as approved by the Ordinary General Meeting of May 19, 2022.

Key Points: 
  • Pursuant to Article 241-2 of the AMF General Regulations (Rglement Gnral de lAutorit des marchs financiers), the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the Company) as approved by the Ordinary General Meeting of May 19, 2022.
  • Maximum proportion of capital that may be purchased by the Company: 10% of the total number of shares comprising the share capital at any time.
  • Duration of the program: 18 months from the Ordinary General Meeting of May 19, 2022.
  • The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation.

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

Retrieved on: 
Monday, May 16, 2022
Part, European Investment Bank, Company, IVA, Pharmacology, NASH, ISIN, Nasdaq, Degenerative disease, Patient, Biology, AbbVie, SGLT2, Phase, Pharmacokinetics, USD, Computational chemistry, COVID-19, Adult, Mucopolysaccharidosis, Fatty liver disease, Research, MPS, Psoriasis, Conference, T2D, Type 2 diabetes, Chronic liver disease, Empagliflozin, Group, Factor X, VI, Online gambling, Pharmaceutical industry, Cryptocurrency, Video game, EU, Euronext Paris, NAFLD

R&D expenses for the first quarter, mainly driven by the development of lanifibranor in NASH, were up 74% compared to the first quarter of 2022.

Key Points: 
  • R&D expenses for the first quarter, mainly driven by the development of lanifibranor in NASH, were up 74% compared to the first quarter of 2022.
  • This significant increase in R&D expenses is driven by the costs associated with the NATiV3 Phase III clinical trial with lanifibranor in NASH.
  • Net cash used in investing activities for the first quarter of 2022 amounted to 0.1 million, compared to 1.1 million in the first quarter of 2021.
  • No net cash from financing activities was generated over the first quarter of 2022, same as for the first quarter of 2021.

Inventiva secures a €50 million credit facility from the European Investment Bank

Retrieved on: 
Monday, May 16, 2022
Single-tranche CDO, European Investment Bank, COVID-19, Company, IVA, Pharmacology, NASH, ISIN, Nasdaq, Exercise, Degenerative disease, Patient, Investment, AbbVie, Biology, Vaccine, Phase, Pharmacokinetics, Computational chemistry, Adult, Mucopolysaccharidosis, Fatty liver disease, Research, MPS, Climate, Partnership, Chronic liver disease, Union, EIB, Factor X, VI, Achievement, Pharmaceutical industry, Security (finance), EU, Euronext Paris

The facility is divided into two tranches of 25 million each.

Key Points: 
  • The facility is divided into two tranches of 25 million each.
  • The disbursement of the first tranche (Tranche A) is subject to the completion of certain conditions precedent specified in the credit facility agreement.
  • The maturity date of any borrowings under the facility is four years after disbursement of Tranche A and three years after disbursement of Tranche B.
  • Jean Volatier, Chief Financial Officer of Inventiva, stated: We are very pleased with this credit facility, one of the largest granted by the EIB to a biotech.

Quantori Announces Powerful HPC Accelerator to Advance Biopharma R&D

Retrieved on: 
Thursday, May 5, 2022
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Other Science, Research, Software, Nanotechnology, Science, LLC, Computational chemistry, Health, Drug discovery, RNA-Seq, ISCB Senior Scientist Award, List, HPC, Poster, Computing, Environment, Genomics, Cryogenic electron microscopy, Data science, Protein folding, Science, Supercomputer, Conference, Solution, CEO, AI, Social media, Pharmaceutical industry, Facebook

HPC is a breakthrough for biopharma companies to compute vast amounts of data to unlock insights and create value, said Richard Golob, CEO, Quantori.

Key Points: 
  • HPC is a breakthrough for biopharma companies to compute vast amounts of data to unlock insights and create value, said Richard Golob, CEO, Quantori.
  • Quantoris HPC solutions include a new Computation Platform Accelerator for applications in genomics, CHIP-seq and RNA-seq, cell image analysis, CryoEM, and computational chemistry.
  • Quantoris HPC Accelerator provides scientists with a convenient environment for advancing their early-stage research without having to focus on infrastructure, bridging the gap between science and IT, explained Mikhail Serkov, Senior Director, HPC Services, Quantori.
  • For more information on Quantoris HPC Accelerator, see the HPC Poster Presentation online and at the Bio-IT World Conference & Expo, and visit the Quantori website at https://quantori.com/expertise/hpc .

REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH

Retrieved on: 
Thursday, April 7, 2022
Molecule, Company, Abstract, Lists of musicians, Red Cloud (rapper), Therapy, PM, Investigational New Drug, Multimedia, Access, TKI, AACR, American Association, EGFR, Food, Laboratory, Computational chemistry, Association, US Foods, Mutation, Drug discovery, AI, Patient, Large-cell lung carcinoma, Pharmaceutical industry, NSCLC, T790M

The data will be presented at the 2022 Annual Meeting of the American Association for Cancer Research (AACR), April 8-13, 2022 in New Orleans.

Key Points: 
  • The data will be presented at the 2022 Annual Meeting of the American Association for Cancer Research (AACR), April 8-13, 2022 in New Orleans.
  • H002 will initially be evaluated for treating C797S mutation-driven resistance to EGFR TKIs in NSCLC.
  • H002 is the first drug candidate expected to enter clinical trials from RedCloud Bio's pipeline.
  • RedCloud Bio is developing a fourth-generation EGFR inhibitor, H002, with a wide spectrum and high selectivity to address the growing unmet needs in NSCLC patients harbouring C797S mutation.

Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of Computational Sciences

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Health, Pharmaceutical, Other Technology, Technology, Therapy, University, LinkedIn, Operation Xcellerator, Leadership, College of Arts and Sciences, Neurology, Growth, Multimedia, Clinical trial, NYSE, JNJ, Cheminformatics, Drug design, LH, NLRP3, Pain scale, Resolve, CEO, Computational chemistry, Artificial intelligence, Industry, Inflammation, University of Tartu, Machine learning, COVID-19, Disease, Chemistry, Drug discovery, Information technology, Protein, J&J, Johnson & Johnson, Fine chemical, Management, Medical device

Ventus Therapeutics , Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences.

Key Points: 
  • Ventus Therapeutics , Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences.
  • View the full release here: https://www.businesswire.com/news/home/20220404005164/en/
    Victor Lobanov, Ph.D., Ventus Senior Vice President, Head of Computational Sciences (Photo: Business Wire)
    Dr. Lobanov brings to Ventus more than 25 years of experience in developing and implementing leading-edge computational methods across the drug discovery continuum.
  • At Ventus, Dr. Lobanov will oversee all scientific and operational aspects of computational sciences and information technology.
  • He will focus on driving the rapid growth of Ventus internal computational capabilities and also help direct the strategy for extending the scope and application of Ventus ReSOLVE platform.

Totus Medicines Announces New San Francisco Bay Area Headquarters & Expanded Lab Space

Retrieved on: 
Thursday, March 31, 2022
People, Cancer, Colon, Lung, Stomach, San Francisco Bay Area, Data science, Growth, Multimedia, Breast, Research, Computational chemistry, Genome, Machine learning, Gene, Chemistry, PI3K, SAN, Ioan Totu, AI, Pharmaceutical industry

SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Totus Medicines, the drug discovery company harnessing proprietary chemical biology and AI to address previously untreatable cancers, today announced the relocation of its headquarters to Emeryville, California. The company is investing heavily in R&D in the coming months, including hiring for 60+ roles across several disciplines, including data science, machine learning, clinical development, and chemistry.

Key Points: 
  • SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Totus Medicines, the drug discovery company harnessing proprietary chemical biology and AI to address previously untreatable cancers, today announced the relocation of its headquarters to Emeryville, California.
  • Totus Medicines' platform uses proprietary molecular tags that track drug binding in individual cells to screen billions of drug molecules across thousands of genes in parallel.
  • Totus Medicines' new 35,000-square-foot facility will include office and lab space for the company's research and development efforts.
  • Totus is based in the San Francisco Bay Area.

IAMA Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, March 31, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Drug development, Therapy, Lists of diseases, University of Rome Tor Vergata, Neuroscience, Disability in Canada, Behavioural sciences, United States Air Force Scientific Advisory Board, Autism, American Academy of Child and Adolescent Psychiatry, Psychiatry, IAMA, Computational chemistry, Neurodevelopmental disorder, Developmental Medicine & Child Neurology, CA, Epilepsy, Drug discovery, SAB, Yale University, Stanford University, University, Neurology, Pharmaceutical industry, Residential care, Child, Chemistry

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today the formation of a Scientific Advisory Board (SAB) consisting of world-renowned experts in computational chemistry, protein drug design, and neurodevelopmental disorders.

Key Points: 
  • IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today the formation of a Scientific Advisory Board (SAB) consisting of world-renowned experts in computational chemistry, protein drug design, and neurodevelopmental disorders.
  • "These thought leaders bring deep scientific expertise in drug discovery and extensive clinical experience in drug development.
  • The founding members of the IAMA Therapeutics' SAB are:
    William L. Jorgensen - Sterling Professor of Chemistry at Yale University (New Haven, CT, USA).
  • More detailed biographies of the Scientific Advisory Board can be found online at:
    IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children suffering from brain disorders.